Fused pentacyclic imidazoles
MA40770AActive Publication Date: 2021-03-24SANOFI SA(FR) +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA40770
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-10-02
- Filing Date
- 2015-10-02
- Publication Date
- 2021-03-24
- Estimated Expiration
- 2035-10-02
Abstract
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and / or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[l,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
Need to check novelty before this filing date? Find Prior Art